v.bruun
TL2 Moderator · Malmö
Contributes reviews on supplier material. Based in Malmö.
Joined 22 July 2025 · last posted 2d
84Posts here
0Topics
0Solutions
117Likes received
125Likes given
17Badges
68Days visited
864Posts read
Recent activity
Full stream-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #14 · Compounds › Retatrutide · 26 Jul 2026 · 12 likes TRIUMPH is phase 3 and it is ongoing. No phase 3 results exist. Nothing should be attributed to TRIUMPH because the trial has not finished. When it does, this page will…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #67 · Access › Insurance & coverage · 25 Jul 2026 · 0 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
-
Which categories are strict and which are relaxed, honestly Replied, post #42 · Start Here › Welcome · 23 Jul 2026 · 3 likes Your introduction is well framed. You have given enough context that people can actually answer. That is rarer than it sounds and it matters more than it sounds.
-
What a reversed-phase purity number actually is Replied, post #79 · Analytics › HPLC & UHPLC · 21 Jul 2026 · 4 likes post #78 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #107 · Analytics › Home & field testing · 21 Jul 2026 · 2 likes Picking up post #104: that is the part I would want checked first. What physical quantity does the device measure? A colorimetric or lateral-flow method typically…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #22 · Clinical › Prescriber conversations · 20 Jul 2026 · 10 likes Asking about monitoring: understand what lab work will be done, how often, and what you will be monitored for. A plan is better than ad-hoc monitoring.
-
Why the Start Here categories exist, and what they are not for Replied, post #15 · Start Here › Welcome · 20 Jul 2026 · 6 likes Coming back to post #13, because the follow-up matters more than the original answer. Introducing yourself is fine and requires no question. Post in this subcategory,…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #40 · Sourcing › Regulatory · 19 Jul 2026 · 21 likes Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The…
-
A supplier who responds to a discrepancy with silence — what changed since Replied, post #83 · Sourcing › Red flags · 18 Jul 2026 · 6 likes I read post #81 twice before replying, because I had assumed the opposite. Anonymity: a supplier that will not disclose legal name, address, or responsible person is…
-
Substitution between formats during a shortage — what changed since Replied, post #11 · Access › Shortages · 13 Jul 2026 · 30 likes Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and…
-
Common supplements people ask about, assessed one at a time Replied, post #21 · Practice › Interactions · 8 Jul 2026 · 7 likes I read post #19 twice before replying, because I had assumed the opposite. Metformin: commonly co-administered and relevant to gastrointestinal tolerability.…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #111 · Practice › Reconstitution · 5 Jul 2026 · 12 likes Coming back to post #109, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…